---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-021966"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:10:16.885929+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abeona Q2 net loss $12.1M; cash runway to 2Q 2023; VIITAL data expected late Q3/early Q4

## Summary
- Net loss $12.1M ($2.08 loss/share) vs $15.2M ($3.93 loss/share) in Q2 2021.
- Cash and investments $26.0M; net cash used in ops $9.0M; runway extended into Q2 2023.
- License revenue $1.0M from Taysha sublicense milestone; R&D $6.7M, G&A $3.5M.
- Phase 3 VIITAL study for EB-101 topline data expected late Q3/early Q4 2022; last patient monitoring mid-September.
- License agreement with Ultragenyx for ABO-102 (MPS IIIA); Abeona eligible for tiered royalties and milestones.

## SEC filing metadata
- accession: 0001493152-22-021966
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315222021966/0001493152-22-021966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315222021966/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-021966
- JSON: https://secwatch.observer/filing/0001493152-22-021966.json
- Plain text: https://secwatch.observer/filing/0001493152-22-021966.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.